Latest from Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute

Ronald B. Natale, MD, discusses the evolution of immunotherapy in advanced non–small cell lung cancer.
Stephen J. Freedland, MD, discusses remaining questions with the real-world utility of enzalutamide in prostate cancer.
Jean Lopategui, MD, discusses the evolution of molecular testing in non–small cell lung cancer.
Karen L. Reckamp, MD, MS, provides insight on how she is navigating challenges posed by the COVID-19 crisis.
Stephen J. Freedland, MD, discusses how real-world evidence with the use of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) compares with data from the phase III PREVAIL trial.
Stephen J. Freedland, MD, discusses the importance of conducting real-world analyses in prostate cancer.
Amin J. Mirhadi, MD, discusses patient populations of lung cancer who should be treated with radiation therapy.
 
Robert A. Figlin, MD, discusses novel combinations in the treatment of patients with kidney cancer.
Publication Bottom Border
Border Publication
x